CD8A and neoplasm: Unexpectedly, although the LELC tumor cells expressed abundant PD-L1, these tumor-specific CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs) mostly did not express PD-1.<h4>Conclusion</h4>Epstein-Barr virus-specific CD8<sup>+</sup> TILs in EBV-driven tumor are heterogeneous and partially lack PD-1 expression, suggesting that anti-PD1/PD-L1 immunotherapy may not be an appropriate strategy for disinhibiting EBV-specific cells in the treatment of LELC patients.